Article
Applied Clinical Trials
With numerous strategic partnerships underway, X-Chem emerges as a leading biotechnology company focused on drug discovery
PPD and X-Chem announced that PPD has exercised its option to acquire the remaining minority ownership interest of X-Chem. X-Chem will continue to operate as a biotechnology company with its entire existing staff, including its management team. PPD acquired a controlling interest in X-Chem in October 2010, along with the right to purchase the remaining interest on or before October 31, 2014. PPD’s decision to acquire the remaining minority interest in X-Chem is based on, among other factors, the successful business model that X-Chem has built and the growing interest by pharmaceutical firms to gain access to X-Chem’s proprietary small molecule discovery technology.
Read the full release here.
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.